PMID- 18998538
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20131121
IS  - 1000-3061 (Print)
IS  - 1000-3061 (Linking)
VI  - 24
IP  - 8
DP  - 2008 Aug
TI  - [Proliferation and cytotoxicity of RetroNectin-activated cytokine-induced killer 
      cells against cisplatin-resistant lung carcinoma cell].
PG  - 1373-80
AB  - To investigate the immunologic characteristics and cytotoxicity of the 
      RetroNectin-activated cytokine-induced killer cells (CIK) against drug-resistant 
      lung cancer cell lines DDP-A549 (DDP: Cisplatin). Peripheral blood mononuclear 
      cells (PBMC) were collected from healthy donors and divided into two groups: 
      group I and group II. Seeded samples of group I into culture flask precoated with 
      RetroNectin and CD3MAb to induce the CIK cells while seeded the group II into 
      culture flask precoated with CD3MAb. In both groups, IFN-gamma was put into the 
      flask on the same day and then IL-2 on the second day. The proliferation of CIK 
      cells was tested by cytometirc analysis. The cytotoxicity activity of CIK cells 
      was determined by MTT assays. The phenotype changes of CIK cells were identified 
      by flow cytometric analysis. Scanning electron microscope (SEM) and transmission 
      electron microscope (TEM) were used to view the cytotoxicity against DDP-A549 of 
      CIK cells and the changes of DDP-A549. The total CIK cells significantly 
      increased by 524.77 fold in cell proliferation number due to the activation to 
      CIK cells of RetroNectin. The expression rate of CD3+CD56+ cells was (31.40 +/- 
      1.91)%. The cytotoxicity of CIK cells showed statistically significance between 
      DDP-A549 and the sensitive strains of parental generation A549 (P < 0.01). There 
      was no significant difference of CIK cells' cytotoxicity between two groups when 
      the effector: target ratio was fixed (P > 0.05). RetroNectin can significantly 
      improve the proliferation activity of CIK cells. There was no evident influence 
      to the cytotoxicity of CIK cells. CIK cells may be used as the immuotherapy to 
      lung adenocarcinoma owing to its significant inhibition to the proliferation of 
      DDP-A549.
FAU - Ren, Wei
AU  - Ren W
AD  - Cancer Research Institute of Harbin Medical University, Harbin 150081, China.
FAU - Wang, Zhihua
AU  - Wang Z
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Sheng Wu Gong Cheng Xue Bao
JT  - Sheng wu gong cheng xue bao = Chinese journal of biotechnology
JID - 9426463
RN  - 0 (Fibronectins)
RN  - 0 (Recombinant Proteins)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adenocarcinoma/immunology/pathology
MH  - Cisplatin/pharmacology
MH  - Cytokine-Induced Killer Cells/*cytology/*immunology
MH  - Cytotoxicity, Immunologic
MH  - Drug Resistance, Neoplasm
MH  - Fibronectins/metabolism/*pharmacology
MH  - Humans
MH  - Lung Neoplasms/immunology/*pathology
MH  - Recombinant Proteins/pharmacology
MH  - Tumor Cells, Cultured
EDAT- 2008/11/13 09:00
MHDA- 2009/09/25 06:00
CRDT- 2008/11/13 09:00
PHST- 2008/11/13 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
PHST- 2008/11/13 09:00 [entrez]
PST - ppublish
SO  - Sheng Wu Gong Cheng Xue Bao. 2008 Aug;24(8):1373-80.